Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets remain in red
Thu, 20 Jun 11:30 am

Indian share markets have remained in red during the previous two hours of trade with realty and metals facing the maximum selling pressures.

The BSE Sensex is down by 377 points and NSE-Nifty is down by 124 points. BSE Mid Cap is down by 1.3% and BSE Small Cap is down by 1.2%. The rupee is trading at 59.68 to the US dollar.

Except Force Motors, all Automobiles shares have slipped in red with Escorts and M&M facing the maximum selling pressures. According to a leading financial news medium, Tata Motors has gone all out in expanding its product portfolio by launching eight new car models across five platforms at its Pimpri plant in Pune. While these are no new launches, but rather the upgrades of existing cars, the management is confident of uptick in sales. The beginning of the all new Tata Motors as exclaimed by the MD, Karl Slym, comes as an inflection point with the launch of eight new products and re-launch of the passenger car business unit. While the company is expected to launch new products in future, currently it intends to focus on upgrading the existing offerings. Given the industry challenges, the company strategizes to continue on the new path and has laid out product portfolio map through 2020. Besides, the company is also enthused about the new top-end Nano launch that will help to revive the falling Nano sales. These initiatives are expected to translate into a strong traction in sales for Tata Motors in the near future. Tata Motors' share is down by 1.8%.

Barring few, most of the Indian Pharma shares have slipped in red with Indoco Remedies and Sun Pharma leading the gains and Fresenius Kabi Onco and Panacea Biotech facing the maximum selling pressures. According to leading financial news daily, Dr Reddy's Laboratories, the Hyderabad-based pharma giant, has been dragged to court in US for allegedly infringing on its patented drug. The company has committed an act of infringement on its patented drug Zemplar (drug used for the prevention and treatment of secondary hyper-parathyroidism associated with chronic renal failure) on six counts concerning three patents. The US Drug maker appealed to the court to pass an order to restrain Dr Reddy's from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing Dr Reddy's generic paricalcitol injectable products prior to the expiration of said patents. Apparently, the company had filed an ANDA (Abbreviated New Drug Application) with the US Food and Drug Administration, seeking approval to sell a generic copy of Zemplar injectable products in 2 microgram/ml and 5 microgram/ml formulations, prior to the expiration of the patents owned by and exclusively licensed to the complainants. This will add to the challenges of Dr Reddy's Laboratories. Dr Reddy's share is down by 0.6%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Indian share markets remain in red". Click here!

  

Related Views on News

TATA MOTORS Announces Quarterly Results (2QFY20); Net Profit Up 117.4% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, TATA MOTORS has posted a net profit of Rs 2 bn (up 117.4% YoY). Sales on the other hand came in at Rs 654 bn (down 9.3% YoY). Read on for a complete analysis of TATA MOTORS's quarterly results.

TATA MOTORS Announces Quarterly Results (1QFY20); Net Profit Down 58.4% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, TATA MOTORS has posted a net profit of Rs 34 bn (down 58.4% YoY). Sales on the other hand came in at Rs 615 bn (down 8.4% YoY). Read on for a complete analysis of TATA MOTORS's quarterly results.

TATA MOTORS 2018-19 Annual Report Analysis (Annual Result Update)

Jul 5, 2019 | Updated on Jul 5, 2019

Here's an analysis of the annual report of TATA MOTORS for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TATA MOTORS. Also includes updates on the valuation of TATA MOTORS.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TATA MOTORS SHARE PRICE


Mar 2, 2021 01:06 PM

TRACK TATA MOTORS

  • Track your investment in TATA MOTORS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

TATA MOTORS - DONGFENG MOTOR COMPARISON

COMPARE TATA MOTORS WITH

MARKET STATS